Johanna Sagemark

AstraZeneca is finding new and innovative ways to use AI to help solve some of the biggest challenges facing the pharmaceutical industry today. To become better, faster, and cheaper in drug discovery and development, we believe in our AI approaches at AstraZeneca to transform R&D. Please join our session to get an overview of some of the real use-cases where AI is having a genuine impact across the R&D value chain:

• Machine learning to predict compound properties to minimize the number of compounds made and tested
• Methods to identify and improve the safety profile of new drugs as well as reduce the costs and time to bring these to the clinic
• AI approaches for discovering patients responding better to treatment
• Designing Molecules using Recurrent Neural Networks and Reinforcement Learning

‍

Johanna is a safety bioinformatician in the Data Science and AI group within Drug Safety and Metabolism at AstraZeneca. Drug design is a multiparameter optimization problem that requires a fine balance between potency, ADME, and safety. Data science and artificial intelligence are potential methods to both improve the safety profile of new drugs as well as reduce the costs and time to bring these to the clinic, and in her talk, Johanna will exemplify its application within drug safety.